TriangleHEALTH PROFESSIONAL · SOURCE READING
Incidence and Mortality
Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: October 25, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: General Information About Thymoma and Thymic Carcinoma Treatment
TETs are relatively rare tumors, representing about 0.2% to 1.5% of all malignancies.[2] The overall incidence of thymoma is 0.13 cases per 100,000 person-years, based on data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program.[3] Thymic carcinomas account for approximately 20% of all TETs.[4] The 5-year survival rate is 36% for patients with inoperable, locally advanced carcinoma and 24% for patients with metastatic thymoma and thymic carcinoma.[5]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice